Acadian Asset Management’s Caribou Biosciences CRBU Stock Holding History

Acadian Asset Management’s Portfolio CRBU Stock Details CRBU Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.75M	Buy	925,039 +865,317	+1,449%	+$1.49M	﹤0.01%	996
2025 Q4	$94K	Buy	+59,722	New	+$125K	﹤0.01%	1684
2025 Q2	–	Sell	-67,725	Closed	-$61K	–	1684
2025 Q1	$61K	Buy	+67,725	New	+$88K	﹤0.01%	1414
2024 Q2	–	Sell	-156,238	Closed	-$802K	–	1770
2024 Q1	$802K	Buy	156,238 +11,921	+8%	+$73.5K	﹤0.01%	904
2023 Q4	$826K	Buy	+144,317	New	+$713K	﹤0.01%	910

Other funds holding CRBU

Pfizer New York $239M AUM 232.47% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Acadian Asset Management's CRBU Position: Q1 2026 in Review

Acadian Asset Management increased its Caribou Biosciences (CRBU) stake by 1,449% in Q1 2026, buying an estimated $1.49M and bringing the position to 925,039 shares worth $1.75M. The position accounts for ﹤0.01% of the portfolio, ranked #996.

Acadian Asset Management first reported a position in CRBU in Q4 2023 and has held it in 5 quarters since. 137 funds tracked by Wall St. Rank hold CRBU as of Q1 2026.

Acadian Asset Management held 925,039 shares of Caribou Biosciences worth $1.75M as of Q1 2026.
Acadian Asset Management bought 865,317 Caribou Biosciences shares in Q1 2026, an estimated $1.49M.
Caribou Biosciences made up ﹤0.01% of Acadian Asset Management's portfolio in Q1 2026, its #996 holding.
Acadian Asset Management first reported a position in Caribou Biosciences in Q4 2023 and has held it in 5 quarters since.
137 funds tracked by Wall St. Rank held Caribou Biosciences as of Q1 2026.

Based on Acadian Asset Management's 13F filing for Q1 2026, filed 13 May 2026.